Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
59.4 USD | +0.41% | +1.02% | -5.40% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.40% | 13.3B | B- | ||
-0.58% | 91.94B | A- | ||
-3.16% | 38.74B | A- | ||
+64.83% | 26.66B | A | ||
-13.98% | 15.32B | C | ||
-11.38% | 11.65B | D+ | ||
+156.85% | 10.37B | D | ||
-49.84% | 10.12B | B | ||
+2.32% | 9.06B | B+ | ||
-18.36% | 7.46B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- INCY Stock
- Ratings Incyte Corporation